Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (761)	3/5/1998 11:26:00 AM
From: maileg	Read Replies (1) \| Respond to of 1826

which would make Richard Bagnell's question about the recent paper on MGI-114's mode of action somewhat prescient: Ahah! Exactly what I was thinking! David, did the person your friend spoke with at MGI state specifically the leukemia comment, or was that his interpretation, based on this paper Richard had quoted? When I read Richard's post, I also wondered whether leukemia would soon enter the clinical picture... Thanks David, that's great news. NCI is very slow; it's good they're taking their own road, too. Darci

To: Biomaven who wrote (761)	3/5/1998 1:18:00 PM
From: seminole	Respond to of 1826

Peter My comments about the CEM leukemia cell line are without documentation and supported by only one authors cell line selection. After reading todays comments, I believe the cell line selected by the company will be the cancer type that will allow the drug to get to market first (not sure which type is most likely). I believe that the NCI will select based upon need for the most number of patients (maybe lung or breast). Sounds like a win-win situation for us shareholders. richard